Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease

COVID-19 is an ongoing worldwide pandemic. Even today, there is a need for the development of effective therapeutic agents. SARS-CoV-2 is known as the causative virus of COVID-19, and its main protease is one of the enzymes essential for its growth and is considered a drug discovery target. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Katagishi, Daiki, Yasuda, Daisuke, Takahashi, Kyoko, Nakamura, Shigeo, Mashino, Tadahiko, Ohe, Tomoyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798672/
https://www.ncbi.nlm.nih.gov/pubmed/36587873
http://dx.doi.org/10.1016/j.bmcl.2022.129121
_version_ 1784860953238568960
author Katagishi, Daiki
Yasuda, Daisuke
Takahashi, Kyoko
Nakamura, Shigeo
Mashino, Tadahiko
Ohe, Tomoyuki
author_facet Katagishi, Daiki
Yasuda, Daisuke
Takahashi, Kyoko
Nakamura, Shigeo
Mashino, Tadahiko
Ohe, Tomoyuki
author_sort Katagishi, Daiki
collection PubMed
description COVID-19 is an ongoing worldwide pandemic. Even today, there is a need for the development of effective therapeutic agents. SARS-CoV-2 is known as the causative virus of COVID-19, and its main protease is one of the enzymes essential for its growth and is considered a drug discovery target. In this study, we evaluated the inhibitory activities of a variety of fullerene derivatives, including newly synthesized derivatives, against the main protease of SARS-CoV-2. As a result, the malonic acid-type fullerene derivatives showed the strongest inhibitory activity.
format Online
Article
Text
id pubmed-9798672
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-97986722022-12-29 Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease Katagishi, Daiki Yasuda, Daisuke Takahashi, Kyoko Nakamura, Shigeo Mashino, Tadahiko Ohe, Tomoyuki Bioorg Med Chem Lett Article COVID-19 is an ongoing worldwide pandemic. Even today, there is a need for the development of effective therapeutic agents. SARS-CoV-2 is known as the causative virus of COVID-19, and its main protease is one of the enzymes essential for its growth and is considered a drug discovery target. In this study, we evaluated the inhibitory activities of a variety of fullerene derivatives, including newly synthesized derivatives, against the main protease of SARS-CoV-2. As a result, the malonic acid-type fullerene derivatives showed the strongest inhibitory activity. Elsevier Ltd. 2023-01-15 2022-12-29 /pmc/articles/PMC9798672/ /pubmed/36587873 http://dx.doi.org/10.1016/j.bmcl.2022.129121 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Katagishi, Daiki
Yasuda, Daisuke
Takahashi, Kyoko
Nakamura, Shigeo
Mashino, Tadahiko
Ohe, Tomoyuki
Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease
title Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease
title_full Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease
title_fullStr Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease
title_full_unstemmed Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease
title_short Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease
title_sort fullerene derivatives as inhibitors of the sars-cov-2 main protease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798672/
https://www.ncbi.nlm.nih.gov/pubmed/36587873
http://dx.doi.org/10.1016/j.bmcl.2022.129121
work_keys_str_mv AT katagishidaiki fullerenederivativesasinhibitorsofthesarscov2mainprotease
AT yasudadaisuke fullerenederivativesasinhibitorsofthesarscov2mainprotease
AT takahashikyoko fullerenederivativesasinhibitorsofthesarscov2mainprotease
AT nakamurashigeo fullerenederivativesasinhibitorsofthesarscov2mainprotease
AT mashinotadahiko fullerenederivativesasinhibitorsofthesarscov2mainprotease
AT ohetomoyuki fullerenederivativesasinhibitorsofthesarscov2mainprotease

Ejemplares similares